Australia markets closed

Assembly Biosciences, Inc. (ASMB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7000-0.0600 (-3.41%)
At close: 04:00PM EST
1.6800 -0.02 (-1.18%)
After hours: 07:14PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.7600
Open1.7600
Bid1.6900 x 1000
Ask1.7000 x 3200
Day's range1.6700 - 1.7600
52-week range1.6700 - 7.0200
Volume968,322
Avg. volume888,030
Market cap81.365M
Beta (5Y monthly)0.66
PE ratio (TTM)N/A
EPS (TTM)-2.6600
Earnings date23 Feb 2022 - 28 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.00
  • GlobeNewswire

    Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced grants of stock options to two new employees to purchase an aggregate of 7,000 shares of the Company’s common stock with an exercise price of $2.45 per share, the closing price of Assembly Bio’s common stock on January 3, 2022. The stock option

  • GlobeNewswire

    Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced that John McHutchison, AO, MD, chief executive officer and president, will present during the HC Wainwright Virtual BIOCONNECT Conference, January 10-13, 2022. The presentation will be available for on-demand viewing beginning Monday, January 1

  • GlobeNewswire

    Assembly Biosciences Outlines Anticipated 2022 Pipeline Development Milestones

    SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today outlined anticipated progress and milestones for its development pipeline in 2022. “The forward momentum we expect to demonstrate across our R&D portfolio in the New Year is indicative of the strength of our refined strategy and the deep HBV and virologi